Infinity Pharmaceuticals Inc. (NASDAQ:INFI) Director Michael C. Venuti sold 6,250 shares of the stock in a transaction on Friday, March 17th. The stock was sold at an average price of $3.48, for a total value of $21,750.00. Following the sale, the director now owns 50,000 shares of the company’s stock, valued at $174,000. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Shares of Infinity Pharmaceuticals Inc. (NASDAQ:INFI) traded down 5.35% during mid-day trading on Monday, hitting $3.36. The company had a trading volume of 947,938 shares. The firm’s 50-day moving average price is $2.61 and its 200 day moving average price is $1.71. Infinity Pharmaceuticals Inc. has a one year low of $0.84 and a one year high of $6.63. The company’s market capitalization is $169.43 million.
Infinity Pharmaceuticals (NASDAQ:INFI) last released its earnings results on Tuesday, March 14th. The company reported ($0.46) EPS for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.11. Infinity Pharmaceuticals had a net margin of 13.23% and a negative return on equity of 125.20%. During the same quarter last year, the firm posted ($0.80) earnings per share. The firm’s revenue for the quarter was down 100.0% compared to the same quarter last year. Analysts predict that Infinity Pharmaceuticals Inc. will post ($1.12) earnings per share for the current fiscal year.
var userip;Your IP Address: document.write(userip);
A number of hedge funds have recently added to or reduced their stakes in the company. FMR LLC raised its stake in Infinity Pharmaceuticals by 3.7% in the fourth quarter. FMR LLC now owns 1,188,976 shares of the company’s stock worth $1,605,000 after buying an additional 42,476 shares in the last quarter. Numeric Investors LLC raised its stake in Infinity Pharmaceuticals by 5.6% in the fourth quarter. Numeric Investors LLC now owns 779,899 shares of the company’s stock worth $1,053,000 after buying an additional 41,605 shares in the last quarter. Baker BROS. Advisors LP acquired a new stake in Infinity Pharmaceuticals during the third quarter worth approximately $905,000. Oxford Asset Management raised its stake in Infinity Pharmaceuticals by 63.5% in the fourth quarter. Oxford Asset Management now owns 343,172 shares of the company’s stock worth $463,000 after buying an additional 133,310 shares in the last quarter. Finally, Tudor Investment Corp Et Al raised its stake in Infinity Pharmaceuticals by 738.5% in the fourth quarter. Tudor Investment Corp Et Al now owns 165,998 shares of the company’s stock worth $224,000 after buying an additional 146,200 shares in the last quarter. 79.56% of the stock is owned by hedge funds and other institutional investors.
About Infinity Pharmaceuticals
Infinity Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers.
Receive News & Ratings for Infinity Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.